BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.
Effective September 19, 2019, the Company and Hankey Capital LLC (“Hankey Capital”) have entered into a Note Purchase Agreement (the “Agreement”). to the Agreement, Hankey Capital will provide a credit facility to the Company of $1,100,000 to be drawn down by the Company upon notice to Hankey Capital. The Agreement is evidenced by a convertible secured note.
There is filed as part of this report the following exhibit.
Bone Biologics Corp Exhibit
…
To view the full exhibit click here
About BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG)
Bone Biologics Corporation is a biotechnology company. The Company is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX combination product is an osteoinductive recombinant protein that provides target specific control over bone regeneration. The Company’s platform technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology and sports medicine. The Company’s platform technology is UCB-1, a skeletal specific growth factor used in combination with DBX, a demineralized bone matrix from Musculoskeletal Transplant Foundation (MTF). Together, with DBX, or alone, NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The NELL-1/DBX Fusion Device will consist of a single dose vial of NELL-1 recombinant protein freeze dried onto DBX.
